顶部联系方式

Time of issue:2018-03-12 00:00:00

Have Any Questions?  Mabspace BiosciencesInfo@mabspacebio.com 迈博斯生物0512-86861701

搜索
迈博斯生物

语言切换

Time of issue:2019-11-21 00:00:00
这是描述信息

NEWS

>>
>>
Qian Xueming: Mai Bosi is an idea that comes from half a dream and half awake

Qian Xueming: Mai Bosi is an idea that comes from half a dream and half awake

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2019-11-28 14:36
  • Views:

(Summary description)On August 17, 1990, he went to Manhattan with the four hundred dollars he borrowed from his uncle. On September 22, 1997, he joined Amgen to start postdoctoral research. On April 1, 2000, ...

Qian Xueming: Mai Bosi is an idea that comes from half a dream and half awake

(Summary description)On August 17, 1990, he went to Manhattan with the four hundred dollars he borrowed from his uncle. On September 22, 1997, he joined Amgen to start postdoctoral research. On April 1, 2000, ...

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2019-11-28 14:36
  • Views:
Information

On August 17, 1990, he went to Manhattan with the four hundred dollars he borrowed from his uncle. On September 22, 1997, he joined Amgen to start postdoctoral research. On April 1, 2000, he changed from a postdoc to a regular Amgen employee. On October 18, 2012, Maibos Biological Company was incorporated. On January 4, 2013, Maibos Bio officially started operations. "Dr. Xueming Qiang can give any details of his past experience without thinking. Good memory is the biggest feeling after the freelance interview. Far away, the bike I was riding off the chain halfway, I repaired my car and got some oil, but fortunately arrived at the appointed time. The teacher sent it to me after signing the admission notice, and my heartbeat was terrible. "It's easy to be brought in by listening to his story, as if you were there.

Qian Xueming

Founder / CEO of Maibos Biomedical (Suzhou) Co., Ltd.

Dr. Qian founded Maibos Bio in early 2013, established an innovative antibody development platform based on breaking the immune tolerance barrier, and used this to develop a new generation of antibody drugs with intellectual property protection. Dr. Qian joined the Molecular Genetics Department of Amgen Corporation as a post-doctoral researcher in the development of new bioengineering drugs after obtaining a PhD in Albany Medical Center in 1997. He was promoted to a scientist in 2000 and participated in and led a number of new antibody and small molecule research and development projects. He was promoted to chief scientist in 2005. In the next five years, he led the team to develop antibody candidate drugs for chronic renal failure for the first time in the world and applied for a number of global patents. From 2010 to 2012, he served as the R & D president of Shengnoji Medicine, responsible for developing monoclonal antibodies against ERa36 and promoting the application of Icaritin in the treatment of primary liver cancer.

"The postgraduate level mainly studies the development of the cerebral nervous system. Three research articles have been published, and so far, they have been cited as literature and have been cited more than 1,500 times."

Qian Xueming believes that overtaking on curved roads must rely on a strong team. In the past two years, his Maibos Bio has gradually introduced the industry's recognized biomedical talents. The arrival of Pan Guangliang gave Maibos a decent CMC team. "Recently, a colleague who has been a CMC at Genentech for 19 years has joined. Everyone has the vision of internationalization and the best medicine in China. The goals, of course, are optimistic about our antibodies. "The growing team gave Qian Xueming confidence. "Once you enter the clinic, you can demonstrate effectiveness and safety on the indications, so next year will be very interesting." Qian Xueming dug clinical expert Wan Yuntao (character story) to take full charge of clinical trials, which he said His new colleague for the "high student" reassured him that they were classmates of Fudan's biophysics major. Qian Xueming said that he had missed the most fashionable professional qualification in biochemistry, but he met many outstanding students because of the misfortune, and there are many well-known experts in the industry.

 

After graduating from college, Qian Xueming went to New York, USA, following the "outbound tide" to study a postgraduate course in neurobiology at Columbia University. At this time, he became interested in the pharmaceutical industry. After graduating from the doctorate, I chose to go to Amgen to continue my postdoctoral research. In addition to being attracted by the halo of the big pharmaceutical factory, it was also because of the beauty and passion of California. "After submitting my resume, I received a call from Amgen, and I took the liberty to ask, 'How is your postdoc's way out?' The other party immediately sent me his resume and told me that their postdoc's way out is good, you can Stay at Amgen. Because I already have two school offers, one of them is Harvard, and it is difficult to make a choice. I said, 'I don't necessarily go to you.' He said, 'No problem, come and see Look, just come and play, look at your classmates near Los Angeles. The sun is shining here. 'I was passed by him.' I was accustomed to the indifference and seriousness of New Yorkers, the "open" and " relax "make Qian Xueming feel good. "For more than two years as a postdoc, our team often drove over a mountain to lunch at the beach for half an hour at noon, drinking a cold drink, and watching the sea, let alone be comfortable. When we returned to the office at two o'clock, the boss had not come back."

 

"When I was in Amgen, I had the prototype of the current company. It was an idea that I had come up with in a half-dream state, but it was not implemented, it was just an idea."

 

In 2000, Qian Xueming became a regular employee of Amgen. He was promoted to chief scientist five years later and joined an antibody project to treat chronic renal failure. He also ushered in his most important five years in Amgen. He led a team of 15 people, starting with finding targets, producing antigens, screening antibodies, making animal models, and evaluating drugability and safety. "I also have to convince department leaders to get budgets, partners inside and outside the company, and get their support." From a scientific researcher to a real project leader, Qian Xueming has gained valuable growth. "Including project establishment, mobilizing resources, Controlling project risks and leading the team have learned these five years. These experiences have been directly used in my current entrepreneurship. "When developing candidate drugs and applying for a number of global patents. The project came to an end. Qian Xueming chose to leave Amgen on his own initiative. He already knew what he was going to do.

 

At Amgen, Qian Xueming and colleagues usually made dozens of site-directed mutations in the antigen protein after an antibody was identified. One by one, the mutations in the site would destroy the ability of the antibody to bind to the antigen. After finding it, apply again. Patents protect important amino acids. Because a lot of antibodies with different binding sites are made, a large number of amino acid combination patents are occupied by Amgen, which also means that the way for latecomers to do the same target is almost blocked. "Many antibodies with the same target bind to the same epitope, which is likely to lead to: first, the antibody drugs on the market are very similar; second, because the epitope space is relatively narrow, the product is easily restricted by competitors' patents. "Without leaving Amgen, Qian Xueming was considering how to develop a new path in the field of antibody drugs.

 

"That was the idea that suddenly appeared in my mind when the brain was very relaxed." Qian Xueming said, using the basic principles of the development of the immune system, it is difficult to produce antibodies between the same proteins. To improve the ability to produce antibodies, it is necessary to use The "unknown" invaders of the autoimmune system stimulate it. At least 60% of the amino acid sequence is the same between humans and mice. When human proteins are injected into mice, the binding sites of the antibodies often appear in 30% -40% of the different amino acid sequences of humans and mice. The resistance to self-proteins will result in more epitope diversity of the antibody, which may have advantages in terms of drugability and patent protection. Allow developers to have sufficient antibody epitope binding space and be free of competitors' patents To produce the most effective drugs, this is our space for Maibos. "

 

"The project started only in 2014. In terms of market access, it must be behind others, but we will do the second generation and surpass others in terms of efficacy. Our PD-L1 antibody is the only pH-dependent binding in the world. PD-L1 antibody. "

 

In 2010, Qian Xueming returned to China to become senior vice president and head of research and development of Sheng Nuoji Pharmaceutical. For three years, he made more preclinical explorations for a class of new drug Akola and recommended liver cancer indications. " Watching Akoladin enter the phase II clinical trial, apply for a major project, and the financing is almost the same. I think it's too late for me to stop doing things. "

 

With the financial support of angel investors and the government, Maibos Bio was established in Suzhou in the golden autumn of 2012.

 

At the beginning of the establishment, Maibos had no laboratory and animal room, only an empty rough room and the idea that Qian Xueming produced half a year ago. "We have designed many peptides with computer modeling and used outsourcing services to prove "The breakthrough technology of immune tolerance barrier is feasible, and it produces more diverse antibodies that bind epitopes than conventional techniques. Based on this, the best site antibodies are screened."

 

Like most start-ups, Maibos pays two cents. Qian Xueming himself drew drawings for the rough room, chose decoration materials, and designed the company logo. With the completion of laboratories and animal houses, advanced antibody research and development equipment is gradually in place, and an antibody discovery platform based on immune tolerance barrier breakthrough technology is gradually taking shape: it can perform antigen production, antigen modification and immunization, and high-throughput screening. And purification, in vitro and in vivo functional antibody evaluation, antibody engineering optimization. Maibosi began to use this platform to provide outsourcing services for other biopharmaceutical companies to obtain valuable cash flow.

 

"Our platform has not only produced many different epitope-bound antibodies, but also found some pH-dependent antigen-binding antibodies that target PD-L1." Qian Xueming accidentally read an article about the use of A new technology makes a second generation of an antibody, from once every two weeks to once a month. This coincides with Qian Xueming's idea. To be a second-generation antibody with better effect, less toxicity, faster onset, and less dosage, the durability of the pH-dependent antigen-binding antibody meets the requirements.

 

However, the huge investment in antibody drugs made Qian Xueming's team not plan to turn this discovery into a drug. "We serve other companies and earn millions of RMB in a year. We will push an antibody project to the IND stage at least. That's $ 10 million. "But, do you always have to serve others? Qian Xueming once fell into contradiction. Soon, some investors saw the potential of Maibos to develop antibodies. "If I invest in you, do you do it?" Qian Xueming's team spent a long time screening a good drug-dependent pH-dependent antigen binding Antibodies, decided to accept financing to continue, in 2015 Maibos received Lilly Asia Fund 15 million US dollars financing.

 

It took a long time before Maibos decided to accept the investment to identify the antibody. Because pH-dependent antigen-binding antibodies cannot achieve better clinical outcomes and have lower doses, there is no competitive advantage. Therefore, a lot of extra work has been done to verify this antibody before starting CMC. Compared with similar products already approved by Genentech and AstraZeneca, the antitumor effect of the pH-dependent antigen-binding PD-L1 antibody is more obvious, and it does not need high doses to show up, and it will last longer. .

 

"We are preparing to do clinical trials, and we are also in Series B financing. For investors, I hope that he can truly understand our medicine and bring resources, preferably foreign resources. We have broken through the problem of patents. I am confident. To compete on the world stage. "

Scan the QR code to read on your phone

页脚关于我们

Time of issue:2019-11-23 00:00:00

页脚管道

Time of issue:2019-11-23 00:00:00

页脚新闻

Time of issue:2019-11-23 00:00:00

页脚人力资源

Time of issue:2019-11-23 00:00:00

页脚联系方式

Time of issue:2019-11-23 00:00:00

页脚版权

Time of issue:2019-11-23 00:00:00

Copyright © 2019 Mabspace Biosciences All rights reserved

页脚备案

Time of issue:2019-11-23 00:00:00